Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of terpene-enriched THC-free cannabidiol oil in children with ADHD
MOH_2025-04-09_014027Phase 2Recruiting
- Sponsor
- Bazelet Nehushtan
- Start
- Dec 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Bcann ASD in attention deficit hyperactivity disorder (ADHD), sponsored by Bazelet Nehushtan. Primary endpoints: Long-term safety and Long-term efficacy. Started Dec 2024; status: recruiting.
02
Drugs
Bcann ASD
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on MOH_2025-04-09_014027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-09_014027.